Literature DB >> 19264909

PTEN contributes to profound PI3K/Akt signaling pathway deregulation in dystrophin-deficient dog muscle.

Marie Feron1, Laetitia Guevel, Karl Rouger, Laurence Dubreil, Marie-Claire Arnaud, Mireille Ledevin, Lynn A Megeney, Yan Cherel, Vehary Sakanyan.   

Abstract

Duchenne muscular dystrophy is the most common and severe form of muscular dystrophy, and although the genetic basis of this disease is well defined, the overall mechanisms that define its pathogenesis remain obscure. Alterations in individual signaling pathways have been described, but little information is available regarding their putative implications in Duchenne muscular dystrophy pathogenesis. Here, we studied the status of various major signaling pathways in the Golden Retriever muscular dystrophy dog that specifically reproduces the full spectrum of human pathology. Using antibody arrays, we found that Akt1, glycogen synthase kinase-3beta (GSK3beta), 70-kDa ribosomal protein S6 kinase (p70S6K), extracellular signal-regulated kinases 1/2, and p38delta and p38gamma kinases all exhibited decreased phosphorylation in muscle from a 4-month-old animal with Golden Retriever muscular dystrophy, revealing a deep alteration of the phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase pathways. Immunohistochemistry analysis revealed the presence of muscle fibers exhibiting a cytosolic accumulation of Akt1, GSK3beta, and phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (PTEN), an enzyme counteracting PI3K-mediated Akt activation. Enzymatic assays established that these alterations in phosphorylation and expression levels were associated with decreased Akt and increased GSK3beta and PTEN activities. PTEN/GSK3beta-positive fibers were also observed in muscle sections from 3- and 36-month-old animals, indicating long-term PI3K/Akt pathway alteration. Collectively, our data suggest that increased PTEN expression and activity play a central role in PI3K/Akt/GSK3beta and p70S6K pathway modulation, which could exacerbate the consequences of dystrophin deficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264909      PMCID: PMC2671376          DOI: 10.2353/ajpath.2009.080460

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  54 in total

1.  An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy.

Authors:  N J Sharp; J N Kornegay; S D Van Camp; M H Herbstreith; S L Secore; S Kettle; W Y Hung; C D Constantinou; M J Dykstra; A D Roses
Journal:  Genomics       Date:  1992-05       Impact factor: 5.736

2.  Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways.

Authors:  C Rommel; S C Bodine; B A Clarke; R Rossman; L Nunez; T N Stitt; G D Yancopoulos; D J Glass
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

3.  Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo.

Authors:  S C Bodine; T N Stitt; M Gonzalez; W O Kline; G L Stover; R Bauerlein; E Zlotchenko; A Scrimgeour; J C Lawrence; D J Glass; G D Yancopoulos
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

Review 4.  Caveolae and caveolin-3 in muscular dystrophy.

Authors:  F Galbiati; B Razani; M P Lisanti
Journal:  Trends Mol Med       Date:  2001-10       Impact factor: 11.951

5.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.

Authors:  Ken Inoki; Yong Li; Tianquan Zhu; Jun Wu; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

6.  Some protein tyrosine phosphatases target in part to lipid rafts and interact with caveolin-1.

Authors:  A Caselli; B Mazzinghi; G Camici; G Manao; G Ramponi
Journal:  Biochem Biophys Res Commun       Date:  2002-08-23       Impact factor: 3.575

7.  GSK-3beta negatively regulates skeletal myotube hypertrophy.

Authors:  Dharmesh R Vyas; Espen E Spangenburg; Tsghe W Abraha; Thomas E Childs; Frank W Booth
Journal:  Am J Physiol Cell Physiol       Date:  2002-08       Impact factor: 4.249

8.  Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers.

Authors:  Ashok Kumar; Niraj Khandelwal; Rahul Malya; Michael B Reid; Aladin M Boriek
Journal:  FASEB J       Date:  2004-01       Impact factor: 5.191

9.  Association of the polymorphisms in the 5'-untranslated region of PTEN gene with type 2 diabetes in a Japanese population.

Authors:  Hajime Ishihara; Toshiyasu Sasaoka; Syota Kagawa; Shihou Murakami; Kazuhito Fukui; Yukio Kawagishi; Katsuya Yamazaki; Akira Sato; Minoru Iwata; Masaharu Urakaze; Manabu Ishiki; Tsutomu Wada; Saori Yaguchi; Hiroshi Tsuneki; Ikuko Kimura; Masashi Kobayashi
Journal:  FEBS Lett       Date:  2003-11-20       Impact factor: 4.124

10.  Caveolin-3 directly interacts with the C-terminal tail of beta -dystroglycan. Identification of a central WW-like domain within caveolin family members.

Authors:  F Sotgia; J K Lee; K Das; M Bedford; T C Petrucci; P Macioce; M Sargiacomo; F D Bricarelli; C Minetti; M Sudol; M P Lisanti
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

View more
  21 in total

1.  Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in δ-Sarcoglycan-deficient hamsters.

Authors:  Bo He; Ru-hang Tang; Noah Weisleder; Bin Xiao; Zhenhua Yuan; Chuanxi Cai; Hua Zhu; Peihui Lin; Chunping Qiao; Jianbin Li; Christina Mayer; Juan Li; Jianjie Ma; Xiao Xiao
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

2.  Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.

Authors:  Natassia M Vieira; Janelle M Spinazzola; Matthew S Alexander; Yuri B Moreira; Genri Kawahara; Devin E Gibbs; Lillian C Mead; Sergio Verjovski-Almeida; Mayana Zatz; Louis M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 11.205

3.  MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms.

Authors:  Matthew S Alexander; Juan Carlos Casar; Norio Motohashi; Natássia M Vieira; Iris Eisenberg; Jamie L Marshall; Molly J Gasperini; Angela Lek; Jennifer A Myers; Elicia A Estrella; Peter B Kang; Frederic Shapiro; Fedik Rahimov; Genri Kawahara; Jeffrey J Widrick; Louis M Kunkel
Journal:  J Clin Invest       Date:  2014-05-01       Impact factor: 14.808

4.  Activation of AKT signaling promotes cell growth and survival in α7β1 integrin-mediated alleviation of muscular dystrophy.

Authors:  Marni D Boppart; Dean J Burkin; Stephen J Kaufman
Journal:  Biochim Biophys Acta       Date:  2011-01-07

Review 5.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

6.  Reduced IGF signaling prevents muscle cell death in a Caenorhabditis elegans model of muscular dystrophy.

Authors:  Kelly Hyunju Oh; Hongkyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

7.  PTEN Inhibition Ameliorates Muscle Degeneration and Improves Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Feng Yue; Changyou Song; Di Huang; Naagarajan Narayanan; Jiamin Qiu; Zhihao Jia; Zhengrong Yuan; Stephanie N Oprescu; Bruno T Roseguini; Meng Deng; Shihuan Kuang
Journal:  Mol Ther       Date:  2020-09-23       Impact factor: 11.454

8.  Regulation of DMD pathology by an ankyrin-encoded miRNA.

Authors:  Matthew S Alexander; Juan Carlos Casar; Norio Motohashi; Jennifer A Myers; Iris Eisenberg; Robert T Gonzalez; Elicia A Estrella; Peter B Kang; Genri Kawahara; Louis M Kunkel
Journal:  Skelet Muscle       Date:  2011-08-08       Impact factor: 4.912

9.  A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.

Authors:  Gemma L Walmsley; Virginia Arechavala-Gomeza; Marta Fernandez-Fuente; Margaret M Burke; Nicole Nagel; Angela Holder; Rachael Stanley; Kate Chandler; Stanley L Marks; Francesco Muntoni; G Diane Shelton; Richard J Piercy
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

10.  Polymeric nanoparticles functionalized with muscle-homing peptides for targeted delivery of phosphatase and tensin homolog inhibitor to skeletal muscle.

Authors:  Di Huang; Feng Yue; Jiamin Qiu; Meng Deng; Shihuan Kuang
Journal:  Acta Biomater       Date:  2020-10-11       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.